The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries (Q84065231)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

title

The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

1 reference

J Abelsson

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

M Merup

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

G Birgegård

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

O WeisBjerrum

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

L Brinch

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

M Brune

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

P Johansson

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

M Kauppila

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

S Lenhoff

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

M Liljeholm

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

C Malm

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

K Remes

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

L Vindelöv

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

B Andréasson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

Nordic MPD Study Group

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

publication date

9 May 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

31 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

volume

47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

31 January 2020

page(s)

380-386

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21552298%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/bmt.2011.91

31 January 2020

exact match

0 references

cites work

20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Myelofibrosis with myeloid metaplasia: diagnostic definition and prognostic classification for clinical studies and treatment guidelines

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983-99.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Reduced intensity conditioning prior to allogeneic stem cell transplantation in first complete remission is effective in patients with acute myeloid leukemia and an intermediate-risk karyotype

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Outcome of transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021

Hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2011.91

7 January 2021